Clinical Breast Cancer Registry of IR. Iran (CBCR-IR): Study Protocol and First Results.

Breast cancer Health policy Hospital Quality indicator Registry

Journal

Archives of Iranian medicine
ISSN: 1735-3947
Titre abrégé: Arch Iran Med
Pays: Iran
ID NLM: 100889644

Informations de publication

Date de publication:
01 Nov 2023
Historique:
received: 18 11 2022
accepted: 06 08 2023
medline: 4 2 2024
pubmed: 4 2 2024
entrez: 4 2 2024
Statut: epublish

Résumé

Breast cancer (BC), as a significant global health problem, is the most common cancer in women. Despite the importance of clinical cancer registries in improving the quality of cancer care and cancer research, there are few reports on them from low- and middle-income countries. We established a multicenter clinical breast cancer registry in Iran (CBCR-IR) to collect data on BC cases, the pattern of care, and the quality-of-care indicators in different hospitals across the country. We established a clinical cancer registry in 12 provinces of Iran. We defined the organizational structure, developed minimal data sets and data dictionaries, verified data sources and registration processes, and developed the necessary registry software. During this registry, we studied the clinical characteristics and outcomes of patients with cancer who were admitted from 2014 onwards. We registered 13086 BC cases (7874 eligible cases) between 1.1.2014 and 1.1.2022. Core needle biopsy from the tumor (61.25%) and diagnostic mammography (68.78%) were the two most commonly used diagnostic methods. Stage distribution was 2.03% carcinoma in situ, 12% stage I, 44.65% stage II, 21.32% stage III, and 4.61% stage IV; stage information was missing in 1532 patients (19.46%). Surgery (95.01%) and chemotherapy (79.65%) were the most common treatments for all patients. The information provided by this registry can be used to evaluate and improve the quality of care for BC patients. It will be scaled up to the national level as an important resource for measuring quality of care and conducting clinical cancer research in Iran.

Sections du résumé

BACKGROUND BACKGROUND
Breast cancer (BC), as a significant global health problem, is the most common cancer in women. Despite the importance of clinical cancer registries in improving the quality of cancer care and cancer research, there are few reports on them from low- and middle-income countries. We established a multicenter clinical breast cancer registry in Iran (CBCR-IR) to collect data on BC cases, the pattern of care, and the quality-of-care indicators in different hospitals across the country.
METHODS METHODS
We established a clinical cancer registry in 12 provinces of Iran. We defined the organizational structure, developed minimal data sets and data dictionaries, verified data sources and registration processes, and developed the necessary registry software. During this registry, we studied the clinical characteristics and outcomes of patients with cancer who were admitted from 2014 onwards.
RESULTS RESULTS
We registered 13086 BC cases (7874 eligible cases) between 1.1.2014 and 1.1.2022. Core needle biopsy from the tumor (61.25%) and diagnostic mammography (68.78%) were the two most commonly used diagnostic methods. Stage distribution was 2.03% carcinoma in situ, 12% stage I, 44.65% stage II, 21.32% stage III, and 4.61% stage IV; stage information was missing in 1532 patients (19.46%). Surgery (95.01%) and chemotherapy (79.65%) were the most common treatments for all patients.
CONCLUSION CONCLUSIONS
The information provided by this registry can be used to evaluate and improve the quality of care for BC patients. It will be scaled up to the national level as an important resource for measuring quality of care and conducting clinical cancer research in Iran.

Identifiants

pubmed: 38310420
doi: 10.34172/aim.2023.90
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

607-617

Informations de copyright

© 2023 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Auteurs

Monireh Sadat Seyyedsalehi (MS)

Department of Medical and Surgical Sciences, University of Bologna, Italy.
Cancer Research Centre, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.

Azin Nahvijou (A)

Cancer Research Centre, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.

Shaghayegh Haghjooy Javanmard (S)

Applied Physiology Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Science, Isfahan, Iran.

Mojtaba Vand Rajabpour (M)

Cancer Research Centre, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.

Amirreza Manteghinejad (A)

Cancer Prevention Research Center, Omid Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.

Habibollah Pirnejad (H)

Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran.
Erasmus School of Health Policy & Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands.

Zahra Niazkhani (Z)

Nephrology and kidney Transplant Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran.

Arash Golpazir Sorkheh (A)

Department of Surgery, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Maryam Baniamer (M)

Department of Chemical Engineering, Amirkabir University of Technology (Tehran Polytechnic), Tehran, Iran.

Jamshid Anasari (J)

Depertment of Radiation Oncology, Arak University of Medical Sciences, Arak, Iran.

Masoud Bahrami (M)

Arak University of Medical Sciences, Arak, Iran.

Maryam Marzban (M)

Clinical Research Development Center, The Persian Gulf Martyrs, Bushehr University of Medical Science, Bushehr, Iran.
Statistical Genetics Lab, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Atefeh Esfandiari (A)

Department of Health Policy and Management, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.

Seyedeh Masoumeh Ghoreishi (SM)

Cellular and Molecular Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

Novin Nikbakhsh (N)

Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

Yahya Baharvand Iran Nia (Y)

Department of Internal Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.

Shahram Ahmadi Somaghian (S)

Shahid Rahimi Hospital, Lorestan University of Medical Sciences, Khorramabad, Iran.

Mohammad Taghi Ashoobi (MT)

Razi Clinical Research Development Unit, Guilan University of Medical Sciences, Rasht, Iran.
Guilan Road Trauma Research Center, Guilan University of Medical Sciences, Rasht, Iran.

Fataneh Bakhshi (F)

Social Determinants of Health Research Center, School of Health, Guilan University of Medical Sciences, Rasht, Iran.

Alireza Ansari-Moghaddam (A)

Health Promotion Research Center, Zahedan University of Medical sciences, Zahedan, Iran.

Mahdieh Bakhshi (M)

Health Promotion Research Center, Zahedan University of Medical sciences, Zahedan, Iran.

Maryam Moradi Binabaj (M)

Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.

Hassan Nourmohammadi (H)

Department of Internal Medicine Shahid Mostafa Khomeini Hospital, Ilam, Iran.

Ramesh Omranipour (R)

Department of Surgical Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.

Kazem Zendehdel (K)

Cancer Research Centre, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.

Classifications MeSH